Recent News

• 09.05.2025 - Xenotransplantation Moving Closer to Becoming a Clinical Reality
• 09.05.2025 - Cantor Global Healthcare Conference
• 08.14.2025 - Xenotransplantation at the brink of breakthrough: A new era in organ transplantation
• 08.14.2025 - Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
• 08.12.2025 - Eledon Pharmaceuticals’ ‘encouraging’ kidney transplant results
• 08.06.2025 - Eledon Pharmaceuticals Updated Phase 1b Tegoprubart Data at WTC 2025
• 08.06.2025 - Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
• 07.30.2025 - Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
• 07.24.2025 - Extending Transplant Life Through Targeted Innovation
• 07.17.2025 - Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

Recent Filings

• 08.14.2025 - 8-K Current report
• 08.14.2025 - 10-Q/A Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - EX-99.1 EX-99.1
• 08.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.14.2025 - 10-K/A Annual report [Section 13 and 15(d), not S-K Item 405]
• 08.06.2025 - 8-K Current report
• 08.06.2025 - EX-99.1 EX-99.1
• 07.29.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.17.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors